Location: Lyon, France, 11 AM EST | 8 AM PST 5 PM CET
Start Date: Jan 20, 2026
Type of Event: Webinars, Just - Evotec Biologics
Attendees:

About the Webinar

High performance cell culture media provide an essential environment to ensure cells are producing high titers and high quality biotherapeutics. These attributes are important drivers in determining whether a biotherapeutic can be manufactured commercially with economics that support market launch.

In this webinar, Just-Evotec Biologics describes their cell culture media, called J.Media, which is a chemically-defined (CD), animal origin free (AOF) Chinese Hamster Ovary (CHO) perfusion cell culture medium designed to maximize productivity and cell viability across scales, while maintaining critical product quality attributes. The proprietary formulation is room temperature stable and able to be concentrated 5x making it attractive for clinical and commercial use at both small and large scale.

J.Media performance was compared to commercially available perfusion media using two IgG1-expressing CHO cell lines in small scale mock perfusion study, and performance scalability was tested from 3 L bench scale to 500 L single use bioreactors (SUB). Results show market-leading volumetric and specific productivity by efficiently funneling nutrients towards protein production while maintaining consistent critical quality attributes (CQAs) including glycans such as high mannose, sialylation, β-galactose, and afucosylation.

Key Takeaways:

  • CHO cell culture medium optimized for perfusion.
  • Available as liquid for pilot scale and powder for large scale manufacturing.
  • Powder is stable up to 24 months at room temperature.

Meet the Presenters:

Arnav Deshpande
RZ Logo Just 220829 RGB color

Arnav Deshpande

Senior Scientist II, Just - Evotec Biologics

RZ Logo Just 220829 RGB color

Latest update: December 2025

Biography

Arnav Deshpande is a senior scientist in the media development team at Just-Evotec Biologics, based in Seattle. He earned his doctoral degree in chemical engineering from Purdue University in 2022, where he engineered microbes to overproduce aromatic amino acids. His interest lies in characterizing cell metabolism using advanced characterization techniques. At Just-Evotec Biologics, his focus is on using high throughput, automated experimental workflows that are informed by data driven in-silico approaches to enable iterative CHO cell culture media development. Prior to this, he worked at a US Department of Energy National Lab where he characterized photosynthetic metabolism using isotopically labeled substrates and metabolomics towards development of sustainable energy solutions. 

RZ Logo Just 220829 RGB color
Matt Stebbins
RZ Logo Just 220829 RGB color

Matthew Stebbins

Media Development Group Lead, Process and Product Development, Just - Evotec Biologics

RZ Logo Just 220829 RGB color

Latest update: December 2025

Biography

Matthew Stebbins is a principal scientist leading Just-Evotec Biologics’ media development and supply organization. In this role, he drives innovation in perfusion cell culture media design to support early- and late-stage process development programs, enabling scalable and cost-efficient biologics manufacturing. Matthew also spearheads technology development initiatives focused on optimizing media for high-intensity perfusion processes, advancing next-generation bioprocessing strategies.
He earned his doctoral in chemical engineering from the University of Wisconsin–Madison in 2017, where his research centered on tissue engineering and in vitro blood-brain barrier models for pharmaceutical development applications. This foundation in complex biological systems informs his approach to designing robust, high-performance perfusion media solutions for therapeutic protein production.
Prior to joining Just-Evotec Biologics, Matthew led end-to-end process development for viral vector raw materials in first-in-human cell and gene therapy programs at Bristol Myers Squibb. His experience spans upstream process development, raw material characterization, and cross-functional collaboration to accelerate timelines for cell and cell-derived therapies.
Matthew is passionate about leveraging data-driven approaches and systems-level thinking to improve bioprocess efficiency and reliability. His leadership in media development continues to shape strategies that reduce manufacturing costs and enhance flexibility for global biologics supply.  

RZ Logo Just 220829 RGB color

Arrange a Meeting with Us